High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkae472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Ontlametse T Choga und 24 weiteren Autor:innen. Beteiligte Einrichtung: Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, HIV Infections, Drug Resistance, Viral, HIV-1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill & Melinda Gates Foundation, Trials of Excellence in Southern Africa, NIAID NIH HHS.
Abstract (Originalsprache)
Objectives
We assessed HIV-1 drug resistance profiles among people living with HIV (PLWH) with detectable viral load (VL) and on dolutegravir-based antiretroviral therapy (ART) in Botswana.
Methods
The study utilised available 100 residual HIV-1 VL samples from unique PLWH in Francistown who had viraemia at-least 6 months after initiating ART in Botswana’s national ART program from November 2023 to January 2024. Viraemia was categorized as low-level viraemia (LLV) (VL: 200–999 copies/mL) or virologic failure (VF) (VL ≥1000 copies/mL). HIV-1 protease, reverse transcriptase and integrase genes were sequenced using an in-house next-generation sequencing Oxford nanopore technology. HIV-1 drug resistance mutations (DRMs) were identified using the HIVdb Program in the Stanford HIV drug resistance database and compared between VL groups.
Results
Among 100 participants, 83.0% were on dolutegravir-based, 10.0% were on non-dolutegravir-based ART and 7.0% had unknown/undocumented ART regimens. Thirty (30%) participants had LLV and 70 (70%) had VF. Among 58 successfully sequenced, 32.8% [95% Confidence Interval (CI): 21.8–46.0] had DRMs to any drug class, 33.3% (4/12) in the LLV group and 32.6% (15/46) in the VF group. Among individuals on dolutegravir-based ART, the overall HIV DRMs were 34.8% (95% CI: 22.7–49.2). By VL groups, 40.0% (95% CI: 16.8–68.7) and 33.3% (95% CI: 20.2–50.0) had DRMs at LLV and VF, respectively.
Conclusions
A high but similar prevalence of any DRMs was observed among individuals with LLV and those with VF on dolutegravir-based therapy. Monitoring DRMs in individuals with detectable VL is crucial for preserving dolutegravir-based ART.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
- Department of Medical Sciences, Faculty of Allied Health Professions, University of Botswana, Gaborone, Botswana.
- Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone, Botswana.
- Data Warehouse, Botswana Ministry of Health, Gaborone, Botswana.
- Division of Infectious Diseases, Brigham & Women's Hospital, Boston, MA, USA.
ORCID-Profile: Ontlametse T Choga, Dorcas Maruapula, Irene Gobe, Joseph Makhema, Roger Shapiro, Shahin Lockman, Sikhulile Moyo, Simani Gaseitsiwe
Förderung
- Bill & Melinda Gates Foundation
- Trials of Excellence in Southern Africa
- NIAID NIH HHS
- African Academy of Sciences
- NHGRI NIH HHS
- FIC NIH HHS
- US National Institutes of Health
- Human Health and Heredity in Africa Consortium
Zitieren
APA
Choga, O. T., Lemogang, G. M., Choga, W. T., Muzanywa, G., Shadreck, T. M., Ralegoreng, C., Maruapula, D., Moraka, N. O., Koofhethile, C. K., Mokgethi, P. T., Seru, K., Zuze, B. J. L., Montshosi, P., Gobe, I., Motswaledi, M. S., Musonda, R., Mbulawa, M. B., Makhema, J., Shapiro, R., …, & Gaseitsiwe, S. (2025). High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae472
Vancouver
Choga OT, Lemogang GM, Choga WT, Muzanywa G, Shadreck TM, Ralegoreng C, et al. High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae472
BibTeX
@article{Choga2025,
author = {Choga, Ontlametse T and Lemogang, Goitseone M and Choga, Wonderful T and Muzanywa, Gaonyadiwe and Shadreck, Thembinkosi M and Ralegoreng, Charity and Maruapula, Dorcas and Moraka, Natasha O and Koofhethile, Catherine K and Mokgethi, Patrick T and Seru, Kedumetse and Zuze, Boitumelo J L and Montshosi, Patience and Gobe, Irene and Motswaledi, Modisa S and Musonda, Rosemary and Mbulawa, Mpaphi B and Makhema, Joseph and Shapiro, Roger and Lockman, Shahin and Chebani, Tony and Nawa, Judith and Bochena, Lindani and Moyo, Sikhulile and Gaseitsiwe, Simani},
title = {High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkae472}
}
EUVIMED